Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now presen...

Descripción completa

Detalles Bibliográficos
Autores principales: van Essen, Martijn, Krenning, Eric P., Kam, Boen L., de Herder, Wouter W., van Aken, Maarten O., Kwekkeboom, Dik J.
Formato: Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://www.ncbi.nlm.nih.gov/pubmed/18188559
http://dx.doi.org/10.1007/s00259-007-0688-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://www.ncbi.nlm.nih.gov/pubmed/18188559
http://dx.doi.org/10.1007/s00259-007-0688-7

Ejemplares similares